Preview
Sign-in for full Details 
Sign-in free and Explore the Exciting World of BiomedExperts:
- Over 1.500.000 Profiles
- More than 1.800 Organizations worldwide
- State of the Art Network Visualizations
- Manage your own Profile
- Locate Experts in your Country/Region
- Locate Experts in your 1. and 2. Level Network
- Connect to Experts Worldwide
NetworkView
Dennis Slamon
This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers
together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles
free of charge to researchers worldwide.
Research Profile (preview)
Chemicals & Drugs
Disorders
Physiology
Anatomy
Living Beings
Procedures
Genes & Molecular Sequences
Sign-in to see full Profile
Network (preview)
33
Pegram, Mark
16
Konecny, Gottfried
14
Press, Michael
10
Karlan, Beth
9
Beryt, Malgorzata
8
Finn, Richard
8
Pietras, Richard
8
Untch, Michael
7
Cobleigh, Melody
7
Oh, Juliana
6
Hepp, Hermann
6
Pauletti, Giovanni
5
Shak, Steven
5
Kabbinavar, Fairooz
5
Dering, Judy
Sign-in to see all Coauthors
Publications
Sign-in to see all Publications
Sign in free and see...
Visualized networks:
See your personal network in
sophisticated graphical views
GeoTargeted Searches:
Locate experts around the world
and connect with global collaborators
Research Profiles:
See the visualized research activity
of experts around the globe
Sign-in to see more
Geonetwork of Dennis Slamon (preview)
Cities where this author has publications
Cities where co-authors of this author have publications
Sign-in to see more
All Publications
-
2009: Konecny G E; Glas R; Dering J; Manivong K; Qi J; Finn R S; Yang G R; Hong K-L; Ginther C; Winterhoff B; Gao G; Brugge J; Slamon D J
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells.
British journal of cancer 2009;101(10):1699-708.
-
2009: Slamon Dennis J; Press Michael F
Alterations in the TOP2A and HER2 genes: association with adjuvant anthracycline sensitivity in human breast cancers.
Journal of the National Cancer Institute 2009;101(9):615-8.
-
2009: Kuo Kuan-Ting; Mao Tsui-Lien; Jones Siân; Veras Emanuela; Ayhan Ayse; Wang Tian-Li; Glas Ruth; Slamon Dennis; Velculescu Victor E; Kuman Robert J; Shih Ie-Ming
Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
The American journal of pathology 2009;174(5):1597-601.
-
2009: Sauter Guido; Lee James; Bartlett John M S; Slamon Dennis J; Press Michael F
Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(8):1323-33.
-
2009: Britten Carolyn D; Finn Richard S; Bosserman Linda D; Wong Steven G; Press Michael F; Malik Mubashira; Lum Bert L; Slamon Dennis J
A phase I/II trial of trastuzumab plus erlotinib in metastatic HER2-positive breast cancer: a dual ErbB targeted approach.
Clinical breast cancer 2009;9(1):16-22.
-
2008: Fejzo Marlena S; Dering Judy; Ginther Chuck; Anderson Lee; Ramos Lilian; Walsh Christine; Karlan Beth; Slamon Dennis J
Comprehensive analysis of 20q13 genes in ovarian cancer identifies ADRM1 as amplification target.
Genes, chromosomes & cancer 2008;47(10):873-83.
-
2008: Walsh Christine S; Ogawa Seishi; Karahashi Hisae; Scoles Daniel R; Pavelka James C; Tran Hang; Miller Carl W; Kawamata Norihiko; Ginther Charles; Dering Judy; Sanada Masashi; Nannya Yasuhito; Slamon Dennis J; Koeffler H Phillip; Karlan Beth Y
ERCC5 is a novel biomarker of ovarian cancer prognosis.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(18):2952-8.
-
2008: Watanabe Masaru; Fiji Hannah D G; Guo Lea; Chan Lai; Kinderman Sape S; Slamon Dennis J; Kwon Ohyun; Tamanoi Fuyuhiko
Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds.
The Journal of biological chemistry 2008;283(15):9571-9.
-
2008: Konecny G E; Venkatesan N; Yang G; Dering J; Ginther C; Finn R; Rahmeh M; Fejzo M Schoenberg; Toft D; Jiang S-W; Slamon D J; Podratz K C
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells.
British journal of cancer 2008;98(6):1076-84.
-
2008: Britten Carolyn D; Kabbinavar Fairooz; Hecht J Randolph; Bello Carlo L; Li Jim; Baum Charles; Slamon Dennis
A phase I and pharmacokinetic study of sunitinib administered daily for 2 weeks, followed by a 1-week off period.
Cancer chemotherapy and pharmacology 2008;61(3):515-24.
-
2008: Oh Juliana J; Boctor Baher N; Jimenez Cynthia A; Lopez Roberto; Koegel Ashley K; Taschereau Eileen O; Phan Diana T; Jacobsen Steven E; Slamon Dennis J
Promoter methylation study of the H37/RBM5 tumor suppressor gene from the 3p21.3 human lung cancer tumor suppressor locus.
Human genetics 2008;123(1):55-64.
-
2008: Wu Yanyuan; Mohamed Hezla; Chillar Ram; Ali Ishrat; Clayton Sheila; Slamon Dennis; Vadgama Jaydutt V
Clinical significance of Akt and HER2/neu overexpression in African-American and Latina women with breast cancer.
Breast cancer research : BCR 2008;10(1):R3.
-
2008: Shepard H M; Jin P; Slamon D J; Pirot Z; Maneval D C
Herceptin.
Handbook of experimental pharmacology 2008;(181):183-219.
-
2007: Milstein Marc; Mooser Chelsea K; Hu Hailiang; Fejzo Marlena; Slamon Dennis; Goodglick Lee; Dry Sarah; Colicelli John
RIN1 is a breast tumor suppressor gene.
Cancer research 2007;67(24):11510-6.
-
2007: Finn Richard S; Dering Judy; Ginther Charles; Wilson Cindy A; Glaspy Padraic; Tchekmedyian Nishan; Slamon Dennis J
Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/"triple-negative" breast cancer cell lines growing in vitro.
Breast cancer research and treatment 2007;105(3):319-26.
-
2007: Oh Juliana J; Koegel Ashley K; Phan Diana T; Razfar Ali; Slamon Dennis J
The two single nucleotide polymorphisms in the H37/RBM5 tumour suppressor gene at 3p21.3 correlated with different subtypes of non-small cell lung cancers.
Lung cancer (Amsterdam, Netherlands) 2007;58(1):7-14.
-
2007: Jones Lee W; Haykowsky Mark; Peddle Carolyn J; Joy Anil A; Pituskin Edith N; Tkachuk Linda M; Courneya Kerry S; Slamon Dennis J; Mackey John R
Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2007;16(5):1026-31.
-
2007: Hinestrosa M Carolina; Dickersin Kay; Klein Pamela; Mayer Musa; Noss Karin; Slamon Dennis; Sledge George; Visco Frances M
Shaping the future of biomarker research in breast cancer to ensure clinical relevance.
Nature reviews. Cancer 2007;7(4):309-15.
-
2007: Munster Pamela N; Britten Carolyn D; Mita Monica; Gelmon Karen; Minton Susan E; Moulder Stacy; Slamon Dennis J; Guo Feng; Letrent Stephen P; Denis Louis; Tolcher Anthony W
First study of the safety, tolerability, and pharmacokinetics of CP-724,714 in patients with advanced malignant solid HER2-expressing tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(4):1238-45.
-
2006: Robert Nicholas; Leyland-Jones Brian; Asmar Lina; Belt Robert; Ilegbodu Des; Loesch David; Raju Robert; Valentine Elizabeth; Sayre Robert; Cobleigh Melody; Albain Kathy; McCullough Cecelia; Fuchs Lea; Slamon Dennis
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(18):2786-92.
-
2006: Oh Juliana J; Razfar Ali; Delgado Idolina; Reed Rebecca A; Malkina Anna; Boctor Baher; Slamon Dennis J
3p21.3 tumor suppressor gene H37/Luca15/RBM5 inhibits growth of human lung cancer cells through cell cycle arrest and apoptosis.
Cancer research 2006;66(7):3419-27.
-
2006: Hurley Judith; Doliny Philomena; Reis Isildinha; Silva Orlando; Gomez-Fernandez Carmen; Velez Pedro; Pauletti Giovanni; Powell Jodeen E; Pegram Mark D; Slamon Dennis J
Docetaxel, cisplatin, and trastuzumab as primary systemic therapy for human epidermal growth factor receptor 2-positive locally advanced breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(12):1831-8.
-
2006: Ryan B M; Konecny G E; Kahlert S; Wang H-J; Untch M; Meng G; Pegram M D; Podratz K C; Crown J; Slamon D J; Duffy M J
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(4):597-604.
-
2006: Slamon Dennis J; Romond Edward H; Perez Edith A;
Advances in adjuvant therapy for breast cancer.
Clinical advances in hematology & oncology : H&O 2006;4(3 Suppl 7):suppl 1, 4-9; discussion suppl 10; quiz 2 p following suppl 10.
-
2006: Konecny Gottfried E; Pegram Mark D; Venkatesan Natarajan; Finn Richard; Yang Guorong; Rahmeh Martina; Untch Michael; Rusnak David W; Spehar Glenn; Mullin Robert J; Keith Barry R; Gilmer Tona M; Berger Mark; Podratz Karl C; Slamon Dennis J
Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumab-treated breast cancer cells.
Cancer research 2006;66(3):1630-9.
-
2005: Byrne Jennifer A; Balleine Rosemary L; Schoenberg Fejzo Marlena; Mercieca Janelle; Chiew Yoke-Eng; Livnat Yael; St Heaps Luke; Peters Gregory B; Byth Karen; Karlan Beth Y; Slamon Dennis J; Harnett Paul; Defazio Anna
Tumor protein D52 (TPD52) is overexpressed and a gene amplification target in ovarian cancer.
International journal of cancer. Journal international du cancer 2005;117(6):1049-54.
-
2005: Burstein H J; Lieberman G; Slamon D J; Winer E P; Klein P
Isolated central nervous system metastases in patients with HER2-overexpressing advanced breast cancer treated with first-line trastuzumab-based therapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(11):1772-7.
-
2005: Press Michael F; Sauter Guido; Bernstein Leslie; Villalobos Ivonne E; Mirlacher Martina; Zhou Jian-Yuan; Wardeh Rooba; Li Yong-Tian; Guzman Roberta; Ma Yanling; Sullivan-Halley Jane; Santiago Angela; Park Jinha M; Riva Alessandro; Slamon Dennis J
Diagnostic evaluation of HER-2 as a molecular target: an assessment of accuracy and reproducibility of laboratory testing in large, prospective, randomized clinical trials.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(18):6598-607.
-
2005: Wilson Cindy A; Slamon Dennis J
Evolving understanding of growth regulation in human breast cancer: interactions of the steroid and peptide growth regulatory pathways.
Journal of the National Cancer Institute 2005;97(17):1238-9.
-
2005: Mass Robert D; Press Michael F; Anderson Steven; Cobleigh Melody A; Vogel Charles L; Dybdal Noël; Leiberman Grazyna; Slamon Dennis J
Evaluation of clinical outcomes according to HER2 detection by fluorescence in situ hybridization in women with metastatic breast cancer treated with trastuzumab.
Clinical breast cancer 2005;6(3):240-6.
-
2005: Oh Juliana J; Boctor Baher; Jimenez Cynthia A; Lopez Roberto C; Razfar Ali; Slamon Dennis J
Use of low-melting-point primers for bisulfite genomic sequencing: analysis of the H37 lung cancer tumor suppressor gene promoter.
Analytical biochemistry 2005;343(2):347-9.
-
2005: Carlson Anne; Berkowitz Jeanne McAdara; Browning Damaris; Slamon Dennis J; Gasson Judith C; Yates Karen E
Expression of c-Fes protein isoforms correlates with differentiation in myeloid leukemias.
DNA and cell biology 2005;24(5):311-6.
-
2005: Carlson Anne; Yates Karen E; Slamon Dennis J; Gasson Judith C
Spatial and temporal changes in the subcellular localization of the nuclear protein-tyrosine kinase, c-Fes.
DNA and cell biology 2005;24(4):225-34.
-
2005: Wilson Cindy A; Cajulis Elaina E; Green Jennifer L; Olsen Taylor M; Chung Young Ah; Damore Michael A; Dering Judy; Calzone Frank J; Slamon Dennis J
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cells.
Breast cancer research : BCR 2005;7(6):R1058-79.
-
2005: Esteva Francisco J; Cheli Carol D; Fritsche Herbert; Fornier Monica; Slamon Dennis; Thiel Robert P; Luftner Diana; Ghani Farooq
Clinical utility of serum HER2/neu in monitoring and prediction of progression-free survival in metastatic breast cancer patients treated with trastuzumab-based therapies.
Breast cancer research : BCR 2005;7(4):R436-43.
-
2004: Bryant Joshua A; Finn Richard S; Slamon Dennis J; Cloughesy Timothy F; Charles Andrew C
EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells.
Cancer biology & therapy 2004;3(12):1243-9.
-
2004: Konecny Gottfried E; Thomssen Christoph; Lück Hans Joachim; Untch Michael; Wang He-Jing; Kuhn Walter; Eidtmann Holger; du Bois Andreas; Olbricht Sigrid; Steinfeld Dieter; Möbus Volker; von Minckwitz Gunter; Dandekar Suganda; Ramos Lillian; Pauletti Giovanni; Pegram Mark D; Jänicke Fritz; Slamon Dennis J
Her-2/neu gene amplification and response to paclitaxel in patients with metastatic breast cancer.
Journal of the National Cancer Institute 2004;96(15):1141-51.
-
2004: Park John W; Kerbel Robert S; Kelloff Gary J; Barrett J Carl; Chabner Bruce A; Parkinson David R; Peck Jonathan; Ruddon Raymond W; Sigman Caroline C; Slamon Dennis J
Rationale for biomarkers and surrogate end points in mechanism-driven oncology drug development.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(11):3885-96.
-
2004: Pegram Mark D; Pienkowski Tadeusz; Northfelt Donald W; Eiermann Wolfgang; Patel Ravi; Fumoleau Pierre; Quan Eleonor; Crown John; Toppmeyer Deborah; Smylie Michael; Riva Alessandro; Blitz Sandra; Press Michael F; Reese David; Lindsay Mary-Ann; Slamon Dennis J
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
Journal of the National Cancer Institute 2004;96(10):759-69.
-
2004: Pegram Mark D; Konecny Gottfried E; O'Callaghan Carminda; Beryt Malgorzata; Pietras Richard; Slamon Dennis J
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
Journal of the National Cancer Institute 2004;96(10):739-49.
-
2004: Oh Juliana J; Fishbein Michael C; Boctor Baher; Jimenez Cynthia A; Lopez Robert; Slamon Dennis J
Evaluation of H37, a candidate 3p21.3 tumor suppressor gene, as a therapeutic and diagnostic marker in lung cancer.
Chest 2004;125(5 Suppl):102S-3S.
-
2004: Tripathy Debu; Slamon Dennis J; Cobleigh Melody; Arnold Andrew; Saleh Mansoor; Mortimer Joanne E; Murphy Maureen; Stewart Stanford J
Safety of treatment of metastatic breast cancer with trastuzumab beyond disease progression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(6):1063-70.
-
2004: Konecny Gottfried E; Meng Y Gloria; Untch Michael; Wang He-Jing; Bauerfeind Ingo; Epstein Melinda; Stieber Petra; Vernes Jean-Michel; Gutierrez Johnny; Hong Kyu; Beryt Malgorzata; Hepp Hermann; Slamon Dennis J; Pegram Mark D
Association between HER-2/neu and vascular endothelial growth factor expression predicts clinical outcome in primary breast cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(5):1706-16.
-
2004: Slamon Dennis J
The FUTURE of ErbB-1 and ErbB-2 pathway inhibition in breast cancer: targeting multiple receptors.
The oncologist 2004;9 Suppl 3():1-3.
-
2003: Konecny Gottfried E; Wilson Cindy A; Slamon Dennis J
Is there a role for epidermal growth factor receptor inhibitors in breast cancer prevention?
Journal of the National Cancer Institute 2003;95(24):1813-5.
-
2003: Konecny Gottfried; Pauletti Giovanni; Pegram Mark; Untch Michael; Dandekar Sugandha; Aguilar Zuleima; Wilson Cindy; Rong Hong-Mei; Bauerfeind Ingo; Felber Margret; Wang He-Jing; Beryt Malgorzata; Seshadri Ram; Hepp Herrmann; Slamon Dennis J
Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer.
Journal of the National Cancer Institute 2003;95(2):142-53.
-
2003: Arboleda M Jane; Lyons John F; Kabbinavar Fairooz F; Bray Mark R; Snow Bryan E; Ayala Raul; Danino Mordechai; Karlan Beth Y; Slamon Dennis J
Overexpression of AKT2/protein kinase Bbeta leads to up-regulation of beta1 integrins, increased invasion, and metastasis of human breast and ovarian cancer cells.
Cancer research 2003;63(1):196-206.
-
2003: Finn Richard S; Slamon Dennis J
Monoclonal antibody therapy for breast cancer: herceptin.
Cancer chemotherapy and biological response modifiers 2003;21():223-33.
-
2002: Elkas John C; Baldwin Rae Lynn; Pegram Mark; Tseng Yiou; Slamon Dennis; Karlan Beth Y
A human ovarian carcinoma murine xenograft model useful for preclinical trials.
Gynecologic oncology 2002;87(2):200-6.
-
2002: Konecny Gottfried; Slamon Dennis J
HER2 testing and correlation with efficacy of trastuzumab therapy.
Oncology (Williston Park, N.Y.) 2002;16(11):1576, 1578.
-
2002: Osoba David; Slamon Dennis J; Burchmore Michael; Murphy Maureen
Effects on quality of life of combined trastuzumab and chemotherapy in women with metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3106-13.
-
2002: Press Michael F; Slamon Dennis J; Flom Kerry J; Park Jinha; Zhou Jian-Yuan; Bernstein Leslie
Evaluation of HER-2/neu gene amplification and overexpression: comparison of frequently used assay methods in a molecularly characterized cohort of breast cancer specimens.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3095-105.
-
2002: Buller Richard E; Shahin Mark S; Horowitz Jo Ann; Runnebaum Ingo B; Mahavni Vikas; Petrauskas Stan; Kreienberg Rolf; Karlan Beth; Slamon Dennis; Pegram Mark
Long term follow-up of patients with recurrent ovarian cancer after Ad p53 gene replacement with SCH 58500.
Cancer gene therapy 2002;9(7):567-72.
-
2002: Buller Richard E; Runnebaum Ingo B; Karlan Beth Y; Horowitz Jo Ann; Shahin Mark; Buekers Thomas; Petrauskas Stan; Kreienberg Rolf; Slamon Dennis; Pegram Mark
A phase I/II trial of rAd/p53 (SCH 58500) gene replacement in recurrent ovarian cancer.
Cancer gene therapy 2002;9(7):553-66.
-
2002: Oh Juliana J; West Alison R; Fishbein Michael C; Slamon Dennis J
A candidate tumor suppressor gene, H37, from the human lung cancer tumor suppressor locus 3p21.3.
Cancer research 2002;62(11):3207-13.
-
2002: Paquette Ronald L; Dergham Sanaa T; Karpf Ellen; Wang He-Jing; Slamon Dennis J; Souza Larry; Glaspy John A
Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery.
Experimental hematology 2002;30(4):374-80.
-
2002: Namazie Ali; Alavi Sassan; Olopade Olufunmilayo I; Pauletti Giovanni; Aghamohammadi Neema; Aghamohammadi M; Gornbein Jeffrey A; Calcaterra Thomas C; Slamon Dennis J; Wang Marilene B; Srivatsan Eri S
Cyclin D1 amplification and p16(MTS1/CDK4I) deletion correlate with poor prognosis in head and neck tumors.
The Laryngoscope 2002;112(3):472-81.
-
2002: Shawver Laura K; Slamon Dennis; Ullrich Axel
Smart drugs: tyrosine kinase inhibitors in cancer therapy.
Cancer cell 2002;1(2):117-23.
-
2002: Vogel Charles L; Cobleigh Melody A; Tripathy Debu; Gutheil John C; Harris Lyndsay N; Fehrenbacher Louis; Slamon Dennis J; Murphy Maureen; Novotny William F; Burchmore Michael; Shak Steven; Stewart Stanford J; Press Michael
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(3):719-26.
-
2001: Schoenberg Fejzo M; Slamon D J
Frozen tumor tissue microarray technology for analysis of tumor RNA, DNA, and proteins.
The American journal of pathology 2001;159(5):1645-50.
-
2001: Singer E; Landgraf R; Horan T; Slamon D; Eisenberg D
Identification of a heregulin binding site in HER3 extracellular domain.
The Journal of biological chemistry 2001;276(47):44266-74.
-
2001: Aguilar Z; Slamon D J
The transmembrane heregulin precursor is functionally active.
The Journal of biological chemistry 2001;276(47):44099-107.
-
2001: Konecny G; Fritz M; Untch M; Lebeau A; Felber M; Lude S; Beryt M; Hepp H; Slamon D; Pegram M
HER-2/neu overexpression and in vitro chemosensitivity to CMF and FEC in primary breast cancer.
Breast cancer research and treatment 2001;69(1):53-63.
-
2001: Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(8):2448-57.
-
2001: Bergman I; Barmada M A; Griffin J A; Slamon D J
Treatment of meningeal breast cancer xenografts in the rat using an anti-p185/HER2 antibody.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(7):2050-6.
-
2001: Konecny G; Untch M; Slamon D; Beryt M; Kahlert S; Felber M; Langer E; Lude S; Hepp H; Pegram M
Drug interactions and cytotoxic effects of paclitaxel in combination with carboplatin, epirubicin, gemcitabine or vinorelbine in breast cancer cell lines and tumor samples.
Breast cancer research and treatment 2001;67(3):223-33.
-
2001: Konecny G; Untch M; Pihan A; Kimmig R; Gropp M; Stieber P; Hepp H; Slamon D; Pegram M
Association of urokinase-type plasminogen activator and its inhibitor with disease progression and prognosis in ovarian cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1743-9.
-
2001: Chan K C; Knox W F; Gandhi A; Slamon D J; Potten C S; Bundred N J
Blockade of growth factor receptors in ductal carcinoma in situ inhibits epithelial proliferation.
The British journal of surgery 2001;88(3):412-8.
-
2001: Slamon D J; Leyland-Jones B; Shak S; Fuchs H; Paton V; Bajamonde A; Fleming T; Eiermann W; Wolter J; Pegram M; Baselga J; Norton L
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
The New England journal of medicine 2001;344(11):783-92.
-
2001: Slamon D; Pegram M
Rationale for trastuzumab (Herceptin) in adjuvant breast cancer trials.
Seminars in oncology 2001;28(1 Suppl 3):13-9.
-
2001: Nabholtz J M; Slamon D
New adjuvant strategies for breast cancer: meeting the challenge of integrating chemotherapy and trastuzumab (Herceptin).
Seminars in oncology 2001;28(1 Suppl 3):1-12.
-
2001: Vogel C; Cobleigh M A; Tripathy D; Gutheil J C; Harris L N; Fehrenbacher L; Slamon D J; Murphy M; Novotny W F; Burchmore M; Shak S; Stewart S J;
First-line, single-agent Herceptin(trastuzumab) in metastatic breast cancer: a preliminary report.
European journal of cancer (Oxford, England : 1990) 2001;37 Suppl 1():S25-9.
-
2001: Lackey D B; Groziak M P; Sergeeva M; Beryt M; Boyer C; Stroud R M; Sayre P; Park J W; Johnston P; Slamon D; Shepard H M; Pegram M
Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase.
Biochemical pharmacology 2001;61(2):179-89.
-
2001: Vogel C L; Cobleigh M A; Tripathy D; Gutheil J C; Harris L N; Fehrenbacher L; Slamon D J; Murphy M; Novotny W F; Burchmore M; Shak S; Stewart S J
First-line Herceptin monotherapy in metastatic breast cancer.
Oncology 2001;61 Suppl 2():37-42.
-
2000: Pegram M D; Lopez A; Konecny G; Slamon D J
Trastuzumab and chemotherapeutics: drug interactions and synergies.
Seminars in oncology 2000;27(6 Suppl 11):21-5; discussion 92-100.
-
2000: Reynolds C P; Wang Y; Melton L J; Einhorn P A; Slamon D J; Maurer B J
Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide.
Medical and pediatric oncology 2000;35(6):597-602.
-
2000: Pauletti G; Dandekar S; Rong H; Ramos L; Peng H; Seshadri R; Slamon D J
Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: a direct comparison of fluorescence in situ hybridization and immunohistochemistry.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(21):3651-64.
-
2000: Pegram M; Slamon D
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
Seminars in oncology 2000;27(5 Suppl 9):13-9.
-
2000: Paquette R L; Dergham S T; Karpf E; Wang H J; Slamon D J; Souza L; Glaspy J A
Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer.
Blood 2000;96(7):2385-90.
-
2000: Strawn L M; Kabbinavar F; Schwartz D P; Mann E; Shawver L K; Slamon D J; Cherrington J M
Effects of SU101 in combination with cytotoxic agents on the growth of subcutaneous tumor xenografts.
Clinical cancer research : an official journal of the American Association for Cancer Research 2000;6(7):2931-40.
-
2000: Slamon D
Herceptin: increasing survival in metastatic breast cancer.
European journal of oncology nursing : the official journal of European Oncology Nursing Society 2000;4(Sa):24-9.
-
2000: Pegram M D; Konecny G; Slamon D J
The molecular and cellular biology of HER2/neu gene amplification/overexpression and the clinical development of herceptin (trastuzumab) therapy for breast cancer.
Cancer treatment and research 2000;103():57-75.
-
1999: Lopez A M; Pegram M D; Slamon D J; Landaw E M
A model-based approach for assessing in vivo combination therapy interactions.
Proceedings of the National Academy of Sciences of the United States of America 1999;96(23):13023-8.
-
1999: Aguilar Z; Akita R W; Finn R S; Ramos B L; Pegram M D; Kabbinavar F F; Pietras R J; Pisacane P; Sliwkowski M X; Slamon D J
Biologic effects of heregulin/neu differentiation factor on normal and malignant human breast and ovarian epithelial cells.
Oncogene 1999;18(44):6050-62.
-
1999: Oh J J; Grosshans D R; Wong S G; Slamon D J
Identification of differentially expressed genes associated with HER-2/neu overexpression in human breast cancer cells.
Nucleic acids research 1999;27(20):4008-17.
-
1999: Cobleigh M A; Vogel C L; Tripathy D; Robert N J; Scholl S; Fehrenbacher L; Wolter J M; Paton V; Shak S; Lieberman G; Slamon D J
Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(9):2639-48.
-
1999: Pegram M D; Slamon D J
Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptor-enhanced chemosensitivity.
Seminars in oncology 1999;26(4 Suppl 12):89-95.
-
1999: Pegram M; Hsu S; Lewis G; Pietras R; Beryt M; Sliwkowski M; Coombs D; Baly D; Kabbinavar F; Slamon D
Inhibitory effects of combinations of HER-2/neu antibody and chemotherapeutic agents used for treatment of human breast cancers.
Oncogene 1999;18(13):2241-51.
-
1999: Pietras R J; Poen J C; Gallardo D; Wongvipat P N; Lee H J; Slamon D J
Monoclonal antibody to HER-2/neureceptor modulates repair of radiation-induced DNA damage and enhances radiosensitivity of human breast cancer cells overexpressing this oncogene.
Cancer research 1999;59(6):1347-55.
-
1999: Wilson C A; Ramos L; Villaseñor M R; Anders K H; Press M F; Clarke K; Karlan B; Chen J J; Scully R; Livingston D; Zuch R H; Kanter M H; Cohen S; Calzone F J; Slamon D J
Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas.
Nature genetics 1999;21(2):236-40.
-
1999: Reissmann P T; Koga H; Figlin R A; Holmes E C; Slamon D J
Amplification and overexpression of the cyclin D1 and epidermal growth factor receptor genes in non-small-cell lung cancer. Lung Cancer Study Group.
Journal of cancer research and clinical oncology 1999;125(2):61-70.
-
1998: Paquette R L; Gonzales E; Yoshimura R; Tran L; Choi R; Baldwin G; Slamon D J; Glaspy J
Ex vivo expansion and differentiation of unselected peripheral blood progenitor cells in serum-free media.
Journal of hematotherapy 1998;7(6):481-91.
-
1998: Pietras R J; Pegram M D; Finn R S; Maneval D A; Slamon D J
Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs.
Oncogene 1998;17(17):2235-49.
-
1998: Pegram M D; Lipton A; Hayes D F; Weber B L; Baselga J M; Tripathy D; Baly D; Baughman S A; Twaddell T; Glaspy J A; Slamon D J
Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1998;16(8):2659-71.
-
1998: Bischoff J R; Anderson L; Zhu Y; Mossie K; Ng L; Souza B; Schryver B; Flanagan P; Clairvoyant F; Ginther C; Chan C S; Novotny M; Slamon D J; Plowman G D
A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers.
The EMBO journal 1998;17(11):3052-65.
-
1998: Challita-Eid P M; Penichet M L; Shin S U; Poles T; Mosammaparast N; Mahmood K; Slamon D J; Morrison S L; Rosenblatt J D
A B7.1-antibody fusion protein retains antibody specificity and ability to activate via the T cell costimulatory pathway.
Journal of immunology (Baltimore, Md. : 1950) 1998;160(7):3419-26.
-
1998: Landgraf R; Pegram M; Slamon D J; Eisenberg D
Cytotoxicity and specificity of directed toxins composed of diphtheria toxin and the EGF-like domain of heregulin beta1.
Biochemistry 1998;37(9):3220-8.
-
1998: Pegram M D; Pauletti G; Slamon D J
HER-2/neu as a predictive marker of response to breast cancer therapy.
Breast cancer research and treatment 1998;52(1-3):65-77.
-
1997: MacGrogan D; Pegram M; Slamon D; Bookstein R
Comparative mutational analysis of DPC4 (Smad4) in prostatic and colorectal carcinomas.
Oncogene 1997;15(9):1111-4.
-
1997: Press M F; Bernstein L; Thomas P A; Meisner L F; Zhou J Y; Ma Y; Hung G; Robinson R A; Harris C; El-Naggar A; Slamon D J; Phillips R N; Ross J S; Wolman S R; Flom K J
HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(8):2894-904.
-
1997: Pegram M D; Finn R S; Arzoo K; Beryt M; Pietras R J; Slamon D J
The effect of HER-2/neu overexpression on chemotherapeutic drug sensitivity in human breast and ovarian cancer cells.
Oncogene 1997;15(5):537-47.
-
1997: Wilson C A; Payton M N; Elliott G S; Buaas F W; Cajulis E E; Grosshans D; Ramos L; Reese D M; Slamon D J; Calzone F J
Differential subcellular localization, expression and biological toxicity of BRCA1 and the splice variant BRCA1-delta11b.
Oncogene 1997;14(1):1-16.
-
1997: Reese D M; Slamon D J
HER-2/neu signal transduction in human breast and ovarian cancer.
Stem cells (Dayton, Ohio) 1997;15(1):1-8.
-
1996: Casey G; Lopez M E; Ramos J C; Plummer S J; Arboleda M J; Shaughnessy M; Karlan B; Slamon D J
DNA sequence analysis of exons 2 through 11 and immunohistochemical staining are required to detect all known p53 alterations in human malignancies.
Oncogene 1996;13(9):1971-81.
-
1996: Li B; Ouyang B; Pan H; Reissmann P T; Slamon D J; Arceci R; Lu L; Dai W
Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas.
The Journal of biological chemistry 1996;271(32):19402-8.
-
1996: Pauletti G; Godolphin W; Press M F; Slamon D J
Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization.
Oncogene 1996;13(1):63-72.
-
1996: Kotts C E; Su F M; Leddy C; Dodd T; Scates S; Shalaby M R; Wirth C M; Giltinan D; Schroff R W; Fritzberg A R; Shepard H M; Slamon D J; Hutchins B M
186Re-labeled antibodies to p185HER2 as HER2-targeted radioimmunopharmaceutical agents: comparison of physical and biological characteristics with 125I and 131I-labeled counterparts.
Cancer biotherapy & radiopharmaceuticals 1996;11(2):133-44.
-
1995: Levin W J; Press M F; Gaynor R B; Sukhatme V P; Boone T C; Reissmann P T; Figlin R A; Holmes E C; Souza L M; Slamon D J
Expression patterns of immediate early transcription factors in human non-small cell lung cancer. The Lung Cancer Study Group.
Oncogene 1995;11(7):1261-9.
-
1995: Pietras R J; Arboleda J; Reese D M; Wongvipat N; Pegram M D; Ramos L; Gorman C M; Parker M G; Sliwkowski M X; Slamon D J
HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells.
Oncogene 1995;10(12):2435-46.
-
1995: Silverstein M J; Poller D N; Waisman J R; Colburn W J; Barth A; Gierson E D; Lewinsky B; Gamagami P; Slamon D J
Prognostic classification of breast ductal carcinoma-in-situ.
Lancet 1995;345(8958):1154-7.
-
1995: Yates K E; Lynch M R; Wong S G; Slamon D J; Gasson J C
Human c-FES is a nuclear tyrosine kinase.
Oncogene 1995;10(6):1239-42.
-
1995: Strohmeyer T; Reese D; Press M; Ackermann R; Hartmann M; Slamon D
Expression of the c-kit proto-oncogene and its ligand stem cell factor (SCF) in normal and malignant human testicular tissue.
The Journal of urology 1995;153(2):511-5.
-
1994: Carbone D P; Mitsudomi T; Chiba I; Piantadosi S; Rusch V; Nowak J A; McIntire D; Slamon D; Gazdar A; Minna J
p53 immunostaining positivity is associated with reduced survival and is imperfectly correlated with gene mutations in resected non-small cell lung cancer. A preliminary report of LCSG 871.
Chest 1994;106(6 Suppl):377S-381S.
-
1994: Levin W J; Casey G; Ramos J C; Arboleda M J; Reissmann P T; Slamon D J
Tumor suppressor and immediate early transcription factor genes in non-small cell lung cancer.
Chest 1994;106(6 Suppl):372S-376S.
-
1994: Press M F; Pike M C; Hung G; Zhou J Y; Ma Y; George J; Dietz-Band J; James W; Slamon D J; Batsakis J G
Amplification and overexpression of HER-2/neu in carcinomas of the salivary gland: correlation with poor prognosis.
Cancer research 1994;54(21):5675-82.
-
1994: Imai Y; Strohmeyer T G; Fleischhacker M; Slamon D J; Koeffler H P
p53 mutations and MDM-2 amplification in renal cell cancers.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1994;7(7):766-70.
-
1994: Pietras R J; Fendly B M; Chazin V R; Pegram M D; Howell S B; Slamon D J
Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells.
Oncogene 1994;9(7):1829-38.
-
1994: Strohmeyer T G; Slamon D J
Proto-oncogenes and tumor suppressor genes in human urological malignancies.
The Journal of urology 1994;151(6):1479-97.
-
1994: Fleischhacker M; Strohmeyer T; Imai Y; Slamon D J; Koeffler H P
Mutations of the p53 gene are not detectable in human testicular tumors.
Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 1994;7(4):435-9.
-
1994: Press M F; Hung G; Godolphin W; Slamon D J
Sensitivity of HER-2/neu antibodies in archival tissue samples: potential source of error in immunohistochemical studies of oncogene expression.
Cancer research 1994;54(10):2771-7.
-
1994: Karlan B Y; Jones J; Slamon D J; Lagasse L D
Glucocorticoids stabilize HER-2/neu messenger RNA in human epithelial ovarian carcinoma cells.
Gynecologic oncology 1994;53(1):70-7.
-
1994: Ronco L V; Silverman S L; Wong S G; Slamon D J; Park L S; Gasson J C
Identification of conserved amino acids in the human granulocyte-macrophage colony-stimulating factor receptor alpha subunit critical for function. Evidence for formation of a heterodimeric receptor complex prior to ligand binding.
The Journal of biological chemistry 1994;269(1):277-83.
-
1993: Aboulafia D M; Feigal E; Vranzian K; Bennett C; Blattner W; Moss A; Slamon D
Human T cell leukemia virus (HTLV-I/II) serodiagnostic testing: disparate results among a cohort of intravenous drug users.
AIDS research and human retroviruses 1993;9(10):1043-50.
-
1993: Reissmann P T; Koga H; Takahashi R; Figlin R A; Holmes E C; Piantadosi S; Cordon-Cardo C; Slamon D J
Inactivation of the retinoblastoma susceptibility gene in non-small-cell lung cancer. The Lung Cancer Study Group.
Oncogene 1993;8(7):1913-9.
-
1993: Kimura E; Enns R E; Alcaraz J E; Arboleda J; Slamon D J; Howell S B
Correlation of the survival of ovarian cancer patients with mRNA expression of the 60-kD heat-shock protein HSP-60.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(5):891-8.
-
1993: Leone A; Seeger R C; Hong C M; Hu Y Y; Arboleda M J; Brodeur G M; Stram D; Slamon D J; Steeg P S
Evidence for nm23 RNA overexpression, DNA amplification and mutation in aggressive childhood neuroblastomas.
Oncogene 1993;8(4):855-65.
-
1992: Chazin V R; Kaleko M; Miller A D; Slamon D J
Transformation mediated by the human HER-2 gene independent of the epidermal growth factor receptor.
Oncogene 1992;7(9):1859-66.
-
1992: De Santes K; Slamon D; Anderson S K; Shepard M; Fendly B; Maneval D; Press O
Radiolabeled antibody targeting of the HER-2/neu oncoprotein.
Cancer research 1992;52(7):1916-23.
-
1992: Aboulafia D M; Bennett C; Koga H; Keith D; Slamon D
Human T-cell leukemia virus type-I/II (HTLV-I/II) serologic testing: the importance of assaying for the full complement of viral antigens.
Viral immunology 1992;5(2):105-11.
-
1992: Park J W; Stagg R; Lewis G D; Carter P; Maneval D; Slamon D J; Jaffe H; Shepard H M
Anti-p185HER2 monoclonal antibodies: biological properties and potential for immunotherapy.
Cancer treatment and research 1992;61():193-211.
-
1991: Tanaka T; Slamon D J; Shimada H; Shimoda H; Fujisawa T; Ida N; Seeger R C
A significant association of Ha-ras p21 in neuroblastoma cells with patient prognosis. A retrospective study of 103 cases.
Cancer 1991;68(6):1296-302.
-
1991: Strohmeyer T; Reissmann P; Cordon-Cardo C; Hartmann M; Ackermann R; Slamon D
Correlation between retinoblastoma gene expression and differentiation in human testicular tumors.
Proceedings of the National Academy of Sciences of the United States of America 1991;88(15):6662-6.
-
1991: Tommasi S; Paradiso A; Mangia A; Barletta A; Simone G; Slamon D J; De Lena M
Biological correlation between HER-2/neu and proliferative activity in human breast cancer.
Anticancer research 1991;11(4):1395-400.
-
1991: Strohmeyer T; Peter S; Hartmann M; Munemitsu S; Ackermann R; Ullrich A; Slamon D J
Expression of the hst-1 and c-kit protooncogenes in human testicular germ cell tumors.
Cancer research 1991;51(7):1811-6.
-
1991: Aboulafia D M; Mitsuyasu R T; Slamon D J
Human T-cell leukemia virus infection in non-intravenous drug using HIV seropositive men in Los Angeles.
AIDS research and human retroviruses 1991;7(3):333-6.
-
1991: Slamon D J
Expression of the nm23 gene and breast cancer prognosis.
Journal of the National Cancer Institute 1991;83(4):229-31.
-
1991: Giovanella B C; Vardeman D M; Williams L J; Taylor D J; de Ipolyi P D; Greeff P J; Stehlin J S; Ullrich A; Cailleau R; Slamon D J
Heterotransplantation of human breast carcinomas in nude mice. Correlation between successful heterotransplants, poor prognosis and amplification of the HER-2/neu oncogene.
International journal of cancer. Journal international du cancer 1991;47(1):66-71.
-
1990: Miller C W; Aslo A; Tsay C; Slamon D; Ishizaki K; Toguchida J; Yamamuro T; Lampkin B; Koeffler H P
Frequency and structure of p53 rearrangements in human osteosarcoma.
Cancer research 1990;50(24):7950-4.
-
1990: Lupu R; Colomer R; Zugmaier G; Sarup J; Shepard M; Slamon D; Lippman M E
Direct interaction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2.
Science (New York, N.Y.) 1990;249(4976):1552-5.
-
1990: Dickson R B; Lippman M E; Slamon D
UCLA colloquium. New insights into breast cancer: the molecular biochemical and cellular biology of breast cancer.
Cancer research 1990;50(14):4446-7.
-
1990: Press M F; Cordon-Cardo C; Slamon D J
Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues.
Oncogene 1990;5(7):953-62.
-
1990: Read L D; Keith D; Slamon D J; Katzenellenbogen B S
Hormonal modulation of HER-2/neu protooncogene messenger ribonucleic acid and p185 protein expression in human breast cancer cell lines.
Cancer research 1990;50(13):3947-51.
-
1990: Natali P G; Nicotra M R; Bigotti A; Venturo I; Slamon D J; Fendly B M; Ullrich A
Expression of the p185 encoded by HER2 oncogene in normal and transformed human tissues.
International journal of cancer. Journal international du cancer 1990;45(3):457-61.
-
1990: Bacus S S; Bacus J W; Slamon D J; Press M F
HER-2/neu oncogene expression and DNA ploidy analysis in breast cancer.
Archives of pathology & laboratory medicine 1990;114(2):164-9.
-
1990: Press M F; Jones L A; Godolphin W; Edwards C L; Slamon D J
HER-2/neu oncogene amplification and expression in breast and ovarian cancers.
Progress in clinical and biological research 1990;354A():209-21.
-
1990: Slamon D J
Studies of the HER-2/neu proto-oncogene in human breast cancer.
Cancer investigation 1990;8(2):253.
-
1989: Anderson D W; Epstein J S; Lee T H; Lairmore M D; Saxinger C; Kalyanaraman V S; Slamon D; Parks W; Poiesz B J; Pierik L T
Serological confirmation of human T-lymphotropic virus type I infection in healthy blood and plasma donors.
Blood 1989;74(7):2585-91.
-
1989: Ehrlich G D; Glaser J B; Abbott M A; Slamon D J; Keith D; Sliwkowski M; Brandis J; Keitelman E; Teramoto Y; Papsidero L
Detection of anti-HTLV-I Tax antibodies in HTLV-I enzyme-linked immunosorbent assay-negative individuals.
Blood 1989;74(3):1066-72.
-
1989: Reissmann P T; Simon M A; Lee W H; Slamon D J
Studies of the retinoblastoma gene in human sarcomas.
Oncogene 1989;4(7):839-43.
-
1989: Slamon D J; Godolphin W; Jones L A; Holt J A; Wong S G; Keith D E; Levin W J; Stuart S G; Udove J; Ullrich A
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.
Science (New York, N.Y.) 1989;244(4905):707-12.
-
1989: Kastan M B; Slamon D J; Civin C I
Expression of protooncogene c-myb in normal human hematopoietic cells.
Blood 1989;73(6):1444-51.
-
1989: Ehrlich G D; Davey F R; Kirshner J J; Sninsky J J; Kwok S; Slamon D J; Kalish R; Poiesz B J
A polyclonal CD4+ and CD8+ lymphocytosis in a patient doubly infected with HTLV-I and HIV-1: a clinical and molecular analysis.
American journal of hematology 1989;30(3):128-39.
-
1988: Norman J T; Bohman R E; Fischmann G; Bowen J W; McDonough A; Slamon D; Fine L G
Patterns of mRNA expression during early cell growth differ in kidney epithelial cells destined to undergo compensatory hypertrophy versus regenerative hyperplasia.
Proceedings of the National Academy of Sciences of the United States of America 1988;85(18):6768-72.
-
1988: Slamon D J; Clark G M
Amplification of c-erbB-2 and aggressive human breast tumors?
Science (New York, N.Y.) 1988;240(4860):1795-8.
-
1988: Rosenblatt J D; Cann A J; Slamon D J; Smalberg I S; Shah N P; Fujii J; Wachsman W; Chen I S
HTLV-II transactivation is regulated by the overlapping tax/rex nonstructural genes.
Science (New York, N.Y.) 1988;240(4854):916-9.
-
1988: Williams A E; Fang C T; Slamon D J; Poiesz B J; Sandler S G; Darr W F; Shulman G; McGowan E I; Douglas D K; Bowman R J
Seroprevalence and epidemiological correlates of HTLV-I infection in U.S. blood donors.
Science (New York, N.Y.) 1988;240(4852):643-6.
-
1988: Fang C T; Williams A E; Sandler S G; Slamon D J; Poiesz B J
Detection of antibodies to human T-lymphotropic virus type 1 (HTLV-1).
Transfusion 1988;28(2):179-83.
-
1988: Slamon D J; Boyle W J; Keith D E; Press M F; Golde D W; Souza L M
Subnuclear localization of the trans-activating protein of human T-cell leukemia virus type I.
Journal of virology 1988;62(3):680-6.
-
1988: Tanaka T; Slamon D J; Shimoda H; Waki C; Kawaguchi Y; Tanaka Y; Ida N
Expression of Ha-ras oncogene products in human neuroblastomas and the significant correlation with a patient's prognosis.
Cancer research 1988;48(4):1030-4.
-
1988: Moss T J; Law Y M; Slamon D J; Brodeur G M; Seeger R C
N-myc protein expression by neuroblastoma cells that have metastasized to bone marrow.
Progress in clinical and biological research 1988;271():91-101.
-
1988: Wada R K; Seeger R C; Brodeur G M; Slamon D J; Rayner S A; Tomayko M; Reynolds C P
Characterization of human neuroblastoma cell lines that lack N-myc gene amplification.
Progress in clinical and biological research 1988;271():57-69.
-
1988: Triche T J; Cavazzana A O; Navarro S; Reynolds C P; Slamon D J; Seeger R E
N-myc protein expression in small round cell tumors.
Progress in clinical and biological research 1988;271():475-85.
-
1988: Seeger R C; Wada R; Brodeur G M; Moss T J; Bjork R L; Sousa L; Slamon D J
Expression of N-myc by neuroblastomas with one or multiple copies of the oncogene.
Progress in clinical and biological research 1988;271():41-9.
-
1987: McGuire W L; Johnson B E; Seeger R C; Slamon D J
Oncogenes in clinical cancer--a panel discussion.
Breast cancer research and treatment 1987;10(3):217-27.
-
1987: Slamon D J
Proto-oncogenes and human cancers.
The New England journal of medicine 1987;317(15):955-7.
-
1987: Tanaka T; Ida N; Waki C; Shimoda H; Slamon D J; Cline M J
Cell type-specific expressions of c-ras gene products in the normal rat.
Molecular and cellular biochemistry 1987;75(1):23-32.
-
1987: Wachsman W; Cann A J; Williams J L; Slamon D J; Souza L; Shah N P; Chen I S
HTLV x gene mutants exhibit novel transcriptional regulatory phenotypes.
Science (New York, N.Y.) 1987;235(4789):674-7.
-
1987: Slamon D J; Clark G M; Wong S G; Levin W J; Ullrich A; McGuire W L
Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
Science (New York, N.Y.) 1987;235(4785):177-82.
-
1987: Fojo A T; Ueda K; Slamon D J; Poplack D G; Gottesman M M; Pastan I
Expression of a multidrug-resistance gene in human tumors and tissues.
Proceedings of the National Academy of Sciences of the United States of America 1987;84(1):265-9.
-
1986: Chan J Y; Slamon D J; Nimer S D; Golde D W; Gasson J C
Regulation of expression of human granulocyte/macrophage colony-stimulating factor.
Proceedings of the National Academy of Sciences of the United States of America 1986;83(22):8669-73.
-
1986: Shah N P; Wachsman W; Cann A J; Souza L; Slamon D J; Chen I S
Comparison of the trans-activation capabilities of the human T-cell leukemia virus type I and II chi proteins.
Molecular and cellular biology 1986;6(11):3626-31.
-
1986: Slamon D J; Boone T C; Murdock D C; Keith D E; Press M F; Larson R A; Souza L M
Studies of the human c-myb gene and its product in human acute leukemias.
Science (New York, N.Y.) 1986;233(4761):347-51.
-
1986: Slamon D J; Boone T C; Seeger R C; Keith D E; Chazin V; Lee H C; Souza L M
Identification and characterization of the protein encoded by the human N-myc oncogene.
Science (New York, N.Y.) 1986;232(4751):768-72.
-
1986: Tanaka T; Ida N; Shimoda H; Waki C; Slamon D J; Cline M J
Organ specific expression of ras oncoproteins during growth and development of the rat.
Molecular and cellular biochemistry 1986;70(1):97-104.
-
1986: Tanaka T; Slamon D J; Battifora H; Cline M J
Expression of p21 ras oncoproteins in human cancers.
Cancer research 1986;46(3):1465-70.
-
1985: Chen I S; Slamon D J; Rosenblatt J D; Shah N P; Quan S G; Wachsman W
The x gene is essential for HTLV replication.
Science (New York, N.Y.) 1985;229(4708):54-8.
-
1985: Slamon D J; Press M F; Souza L M; Murdock D C; Cline M J; Golde D W; Gasson J C; Chen I S
Studies of the putative transforming protein of the type I human T-cell leukemia virus.
Science (New York, N.Y.) 1985;228(4706):1427-30.
-
1985: Tanaka T; Slamon D J; Cline M J
Efficient generation of antibodies to oncoproteins by using synthetic peptide antigens.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(10):3400-4.
-
1985: Shimotohno K; Miwa M; Slamon D J; Chen I S; Hoshino H; Takano M; Fujino M; Sugimura T
Identification of new gene products coded from X regions of human T-cell leukemia viruses.
Proceedings of the National Academy of Sciences of the United States of America 1985;82(2):302-6.
-
1984: Slamon D J; Cline M J
Expression of cellular oncogenes during embryonic and fetal development of the mouse.
Proceedings of the National Academy of Sciences of the United States of America 1984;81(22):7141-5.
-
1984: Slamon D J; Shimotohno K; Cline M J; Golde D W; Chen I S
Identification of the putative transforming protein of the human T-cell leukemia viruses HTLV-I and HTLV-II.
Science (New York, N.Y.) 1984;226(4670):61-5.
-
1984: Cline M J; Slamon D J; Lipsick J S
Oncogenes: implications for the diagnosis and treatment of cancer.
Annals of internal medicine 1984;101(2):223-33.
-
1984: Slamon D J; deKernion J B; Verma I M; Cline M J
Expression of cellular oncogenes in human malignancies.
Science (New York, N.Y.) 1984;224(4646):256-62.
-
1983: Müller R; Slamon D J; Adamson E D; Tremblay J M; Müller D; Cline M J; Verma I M
Transcription of c-onc genes c-rasKi and c-fms during mouse development.
Molecular and cellular biology 1983;3(6):1062-9.
-
1982: Mercola K E; Bar-Eli M; Stang H D; Slamon D J; Cline M J
Insertion of new genetic information into bone marrow cells of mice: comparison of two selectable genes.
Annals of the New York Academy of Sciences 1982;397():272-80.
-
1982: Müller R; Slamon D J; Tremblay J M; Cline M J; Verma I M
Differential expression of cellular oncogenes during pre- and postnatal development of the mouse.
Nature 1982;299(5884):640-4.
-
1982: Bar-Eli M; Mercola K E; Slamon D J; Mauritzson N; Stang H D; Cline M J
Insertion of drug resistance genes in animals.
Journal of cellular physiology. Supplement 1982;1():213-7.
-
1975: Slamon D J
Hemolytic anemia induced by murine erythroblastosis virus: possible mechanisms of hemolysis and effects of an interferon inducer.
Journal of the National Cancer Institute 1975;55(2):329-38.
-
1973: Slamon D J
Protective effect of the double-stranded polyribonucleotide, polyinosinic polycytidylic acid, against rat erythroblastosis induced by murine erythroblastosis virus.
Journal of the National Cancer Institute 1973;51(3):851-63.
Sign-in to see more
